重组人甲状旁腺激素(1-84)治疗甲状旁腺功能减退症:8年前瞻性疗效与安全性研究
结果显示钙剂和活性维生素D需求分别降低57%和76%,尿钙下降38%,肾功能稳定,腰椎和全髋骨密度增加,但股骨颈无变化、桡骨远端骨密度下降。结论认为rhPTH(1-84)是安全有效的长期治疗。
要点
- 8年rhPTH(1-84)治疗使钙剂和活性维生素D需求分别降低57%和76%。
- 治疗期间血钙稳定,尿钙下降38%,eGFR保持稳定。
- 腰椎和全髋骨密度增加,但桡骨远端骨密度下降3.5%。
核心结论
- rhPTH(1-84)治疗甲状旁腺功能减退症8年安全有效,可减少补充剂需求并维持肾功能稳定。
主要发现
- 钙剂需求降低57%(P < 0.01),活性维生素D需求降低76%(P < 0.001)。
- 血钙稳定,尿钙排泄下降38%(P < 0.01),eGFR稳定且与基线eGFR和血钙水平相关。
- 钙磷乘积低于推荐上限,血磷保持正常范围。
- 腰椎骨密度峰值出现在第4年(平均±SE,4.6%±1.5%;P = 0.01),全髋骨密度峰值出现在第8年(2.6%±1.1%;P = 0.02)。
- 股骨颈骨密度无变化,桡骨远端骨密度下降(平均±SE,-3.5%±1.1%;P = 0.001)。
临床怎么用
- 对于传统治疗下出现肾功能下降或骨密度异常的患者,可考虑rhPTH(1-84)长期治疗。
- 治疗中需监测血钙、尿钙、肾功能及不同部位骨密度变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Conventional treatment of hypoparathyroidism is associated with decreased renal function and increased bone mineral density (BMD). OBJECTIVE: To evaluate the effects of 8 years of recombinant human parathyroid hormone (1-84) [rhPTH(1-84)] therapy on key biochemical and densitometric indices. DESIGN: Prospective open-label trial. SETTING: Tertiary medical center. PARTICIPANTS: Twenty-four subjects with hypoparathyroidism. INTERVENTION: Treatment with rhPTH(1-84) for 8 years. MAIN OUTCOME MEASURES: Supplemental calcium and vitamin D requirements, serum calcium and phosphorus levels, calcium-phosphate product, urinary calcium excretion, estimated glomerular filtration rate (eGFR) and BMD. RESULTS: PTH therapy was associated with progressive reduction in supplemental calcium (57%; P < 0.01) and active vitamin D (76%; P < 0.001) requirements over 8 years. Serum calcium concentration was stable; urinary calcium excretion declined 38% (P < 0.01). eGFR remained stable and was related to baseline eGFR and serum calcium levels. Calcium-phosphate product was below the recommended limit; serum phosphorus remained within normal range. Lumbar spine and total hip BMD increased, peaking at 4 (mean ± SE, 4.6% ± 1.5%; P = 0.01) and 8 years (2.6% ± 1.1%; P = 0.02), whereas femoral neck BMD did not change and one-third radius BMD decreased (mean ± SE, -3.5% ± 1.1%; P = 0.001). BMD at all sites was higher throughout the 8 years than in the age- and sex-matched reference population. Hypercalcemia and hypocalcemia were uncommon. CONCLUSION: rhPTH(1-84) is a safe and effective treatment for hypoparathyroidism for 8 years. Long-term reductions in supplemental requirements and biochemical improvements with stable renal function are maintained.
引用
- Tay YD, Tabacco G, Cusano NE, et al. Therapy of Hypoparathyroidism With rhPTH(1-84): A Prospective, 8-Year Investigation of Efficacy and Safety. J Clin Endocrinol Metab. 2019. PMID: 31310310. doi:10.1210/jc.2019-00893
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。